Department of Ob-Gyn, University of New Mexico, Albuquerque, 87131, USA.
Contraception. 2011 Aug;84(2):178-83. doi: 10.1016/j.contraception.2010.11.021. Epub 2011 Jan 20.
The FDA approval of mifepristone in 2000 broadened the available options for abortion. The aim of this study was to evaluate whether physicians in New Mexico have integrated the use of mifepristone into their practice.
We performed a mail-out survey of New Mexico Obstetrician Gynecologists (Ob-Gyn) and Family Medicine (FM) physicians in 2001 and 2008. Questions addressed integration of abortion services, attitudes towards providing abortion in different scenarios and barriers to offering abortion services.
The response rates were 59% for the 2001 survey and 54% in 2008. In 2001 and 2008, 11% and 15% (p=.26) of physicians, respectively, provided any abortion - medical or surgical. Similarly, in 2001 and 2008, 5% and 10% (p=.07) provided medical abortion. Commonly cited barriers to provision of abortion in both years were beliefs against abortion and lack of training.
The number of physicians offering any abortion or medical abortion in New Mexico has not changed since the FDA approval of mifepristone. Residency training programs in FM and in Ob-gyn should include training in medical abortion.
2000 年 FDA 批准米非司酮拓宽了堕胎的可选方案。本研究旨在评估新墨西哥州的医生是否已将米非司酮纳入其常规医疗实践。
我们于 2001 年和 2008 年向新墨西哥州的妇产科医生（Ob-Gyn）和家庭医学（FM）医生进行了邮寄问卷调查。问题涉及堕胎服务的整合、在不同情况下提供堕胎的态度以及提供堕胎服务的障碍。
2001 年的应答率为 59%，2008 年为 54%。在 2001 年和 2008 年，分别有 11%和 15%的医生（p=.26）提供任何形式的堕胎——药物或手术。同样，在 2001 年和 2008 年，分别有 5%和 10%的医生（p=.07）提供药物流产。在这两年中，提供堕胎的常见障碍是反对堕胎的信念和缺乏培训。
自 FDA 批准米非司酮以来，新墨西哥州提供任何堕胎或药物堕胎的医生人数没有变化。FM 和 Ob-Gyn 的住院医师培训计划应包括药物流产培训。
